ReviewOpen medicine (Warsaw, Poland)2025
A review of brain research on T2DM-related cognitive dysfunction.
Review in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Semaglutide Attenuates Type 2 Diabetes-Induced Neurotoxicity by Modulating Neuroinflammation, Oxidative Stress, and Neuroapoptosis.Life (Basel, Switzerland) · 2026Article
- Development and validation of a diagnostic model for mild cognitive impairment in patients with type 2 diabetes mellitus and concomitant white matter hyperintensities.BMC neurology · 2026Article
- Ketogenic metabolic therapy: low-carbohydrate interventions as novel neuroprotective strategies for cognitive dysfunction in diabetes.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This article summarizes the brain research progress and main research techniques of type 2 diabetes mellitus (T2DM) combined with cognitive dysfunction in recent years, aiming to provide new ideas for the mechanism research and treatment of cognitive dysfunction in diabetes. Methods: We performed a systematic literature search using the Google Academic database and the PubMed database and then preparing the manuscript. Results: Cognitive impairment in patients with T2DM is linked to multiple structural alterations in the brain. These alterations encompass cerebral atrophy, vascular damage, increased white matter hyperintensities, microbleeds, a reduction in gray matter volume in the cerebellar cortex, modifications to the structure of the cerebellar dentate nucleus, and frontal cortex damage. Moreover, it may result in neuronal apoptosis and injury, a decline in the generation and maturation of neurons, disrupted or weakened neuronal autophagy, among other consequences. Investigators are employing sophisticated methods such as diffusion tensor imaging, diffusion kurtosis imaging, resting-state functional magnetic resonance imaging, cerebral blood flow examinations, and voxel-based morphometry to investigate these affected brain areas. Discussion: The pathogenesis of T2DM-related cognitive dysfunction is not fully understood. This article reviews recent advances in the study of T2DM-related cognitive dysfunction and highlights key research methodologies, offering new insights into the mechanisms and potential treatments for cognitive impairment in diabetes. This review provides a new direction for the study of the mechanism and treatment of cognitive dysfunction in diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.